Sexual Health Sexual Health Society
Publishing on sexual health from the widest perspective
EDITORIAL

The emerging role of antiretroviral agents in HIV prevention

I. Mary Poynten A B and Andrew E. Grulich A
+ Author Affiliations
- Author Affiliations

A National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Darlinghurst, NSW 2010, Australia.

B Corresponding author. Email: mpoynten@nchecr.unsw.edu.au

Sexual Health 8(2) 137-139 https://doi.org/10.1071/SH10117
Submitted: 17 September 2010  Accepted: 23 September 2010   Published: 18 May 2011


References

[1]  NSW Health Department. Management of non-occupational exposure to blood borne and sexually transmissible diseases. Circular no 98/106. Sydney: NSW Health Department; 1998.

[2]  Australian National Council on AIDS Hepatitis C & Related Diseases (ANCAHRD). Guidelines for the management and post exposure prophylaxis of individuals who sustain nonoccupational exposure to HIV. The ANCAHRD Bulletin 2001. Canberra: ANCAHRD; 2001.

[3]  NPEP Reference Group. National guidelines for post-exposure prophylaxis after non-occupational exposure to HIV. Sex Health 2007; 4 277–83.
National guidelines for post-exposure prophylaxis after non-occupational exposure to HIV.CrossRef | 18200764PubMed |

[4]  Smith D, Grohskopf LA, Black RJ, Auerbach JD, Veronese F, Struble KA, et al Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services. Morb Mort Wkly Rep Recommend Rep 2005; 54 1–20.

[5]  Almeda J, Casabona J, Simon B, Gerard M, Rey D, Puro V, et al Proposed recommendations for the management of HIV postexposure prophylaxis after sexual, injecting drug or other exposures in Europe. Euro Surveill 2004; 9 35–40.
| 1:STN:280:DC%2BD2MrhvVKjtQ%3D%3D&md5=19b1877b0b5566aeb85d55928f5aa057CAS | 15223890PubMed |

[6]  Fisher M, Benn P, Evans B, Pozniak A, Jones M, MacLean S, et al UK guideline for the use of post-exposure prophylaxis for HIV following sexual exposures. Int J STD AIDS 2006; 17 81–92.
UK guideline for the use of post-exposure prophylaxis for HIV following sexual exposures.CrossRef | 16464267PubMed |

[7]  World Health Organization. Post exposure prophylaxis to prevent HIV infection: joint WHO/ILO guidelines on post-exposure prophylaxis (PEP) to prevent HIV infection. Geneva: WHO; 2007. Available from: http://whqlibdoc.who.int/publications/2007/9789241596374_eng.pdf [verified October 2010].

[8]  Poynten I, Smith DE, Cooper DA, Kaldor JM, Grulich AE. The public health impact of widespread availability of nonoccupational postexposure prophylaxis against HIV. HIV Med 2007; 8 374–81.
The public health impact of widespread availability of nonoccupational postexposure prophylaxis against HIV.CrossRef | 1:STN:280:DC%2BD2srgt1Oqtg%3D%3D&md5=3caa65283d330331c8cd638cfd163366CAS | 17661845PubMed |

[9]  Poynten I, Jin F, Mao L, Prestage GP, Kippax SC, Kaldor JM, et al Non-occupational post-exposure prophylaxis, subsequent risk behaviour and HIV incidence in a cohort of Australian homosexual men. AIDS 2009; 23 1119–26.
Non-occupational post-exposure prophylaxis, subsequent risk behaviour and HIV incidence in a cohort of Australian homosexual men.CrossRef | 19417578PubMed |

[10]  Grant R. Antiretroviral agents used by HIV-uninfected persons for prevention: pre- and postexposure prophylaxis. Clin Infect Dis 2010; 50 S96–101.
Antiretroviral agents used by HIV-uninfected persons for prevention: pre- and postexposure prophylaxis.CrossRef | 20397962PubMed |

[11]  Sonder G, van den Hoek A, Regez RM, Brinkman K, Prins JM, Mulder J, et al Trends in HIV postexposure prophylaxis prescription and compliance after sexual exposure in Amsterdam, 2000–2004. Sex Transm Dis 2007; 34 288–93.
Trends in HIV postexposure prophylaxis prescription and compliance after sexual exposure in Amsterdam, 2000–2004.CrossRef | 16980918PubMed |

[12]  Roland M. Postexposure prophylaxis after sexual exposure to HIV. Curr Opin Infect Dis 2007; 20 39–46.
Postexposure prophylaxis after sexual exposure to HIV.CrossRef | 17197880PubMed |

[13]  Schechter M, do Lago RF, Mendelsohn AB, Moreira RI, Moulton LH, Harrison LH. Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV. J Acquir Immune Defic Syndr 2004; 35 519–25.
Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV.CrossRef | 15021317PubMed |

[14]  Martin JN, Roland ME, Neilands TB, Krone MR, Bamberger JD, Kohn RP, et al Use of postexposure prophylaxis against HIV infection following sexual exposure does not lead to increases in high-risk behavior. AIDS 2004; 18 787–92.
Use of postexposure prophylaxis against HIV infection following sexual exposure does not lead to increases in high-risk behavior.CrossRef | 15075514PubMed |

[15]  Kahn J, Martin JN, Roland ME, Bamberger JD, Chesney M, Chambers D, et al Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: the San Francisco PEP study. J Infect Dis 2001; 183 707–14.
Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: the San Francisco PEP study.CrossRef | 1:STN:280:DC%2BD3M7ot1Gqug%3D%3D&md5=45a6d78a407eda5abc3e174329229e8aCAS | 11181146PubMed |

[16]  Bernasconi E, Jost J, Ledergerber B, Hirschel B, Francioli P, Sudre P. Antiretroviral prophylaxis for community exposure to the human immunodeficiency virus in Switzerland, 1997–2000. Swiss Med Wkly 2001; 131 433–7.
| 1:CAS:528:DC%2BD3MXotVWht7c%3D&md5=3f50310583544f04aa6333dba02e6d6dCAS | 11582633PubMed |

[17]  Tissot F, Erard V, Dang T, Cavassini M. Nonoccupational HIV post-exposure prophylaxis: a 10-year retrospective analysis. HIV Med 2010; 11 584–92.
Nonoccupational HIV post-exposure prophylaxis: a 10-year retrospective analysis.CrossRef | 1:STN:280:DC%2BC3cfjtFSruw%3D%3D&md5=8762f51b9f8e42bced3aae4d846dd9f8CAS | 20345883PubMed |

[18]  Roland M, Neilands TB, Krone MR, Katz MH, Franses K, Grant RM, et al Seroconversion following nonoccupational postexposure prophylaxis against HIV. Clin Infect Dis 2005; 41 1507–13.
Seroconversion following nonoccupational postexposure prophylaxis against HIV.CrossRef | 16231265PubMed |

[19]  Cordes C, Moll A, Kuecherer C, Ulrich M. HIV transmission despite HIV post-exposure prophylaxis after non-occupational exposure. AIDS 2004; 18 582–4.
HIV transmission despite HIV post-exposure prophylaxis after non-occupational exposure.CrossRef | 15090822PubMed |

[20]  Montaner J, Hogg R, Wood E, Kerr T, Tyndall M, Levy AR, et al The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet 2006; 368 531–6.
The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic.CrossRef | 16890841PubMed |

[21]  Anema A, Wood E, Montaner J. The use of highly active retroviral therapy to reduce HIV incidence at the population level. CMAJ 2008; 179 13–4.
The use of highly active retroviral therapy to reduce HIV incidence at the population level.CrossRef | 18591515PubMed |

[22]  Global Advocacy for HIV Prevention. Pre-exposure prophylaxis (PrEP). New York: Global Advocacy for HIV Prevention; 2010. Available online at: http://prepwatch.org [verified October 2010].

[23]  Attia S, Egger M, Müller M, Zwahlen M, Low N. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS 2009; 23 1397–404.
Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis.CrossRef | 19381076PubMed |

[24]  Grulich A, Zablotska I. Commentary: probability of HIV transmission through anal intercourse. Int J Epidemiol 2010; 39 1064–5.
Commentary: probability of HIV transmission through anal intercourse.CrossRef | 20511336PubMed |

[25]  Grohskopf L, Gvetadze R, Pathak S, O’Hara B, Mayer K, Liu A, et al. Preliminary analysis of biomedical data from the phase II clinical safety trial of tenofovir disoproxil fumarate (TDF) for HIV-1 pre-exposure prophylaxis (PrEP) among US men who have sex with men (MSM) (Abstract FRLBC102). XVIII International AIDS Conference; 2010 July 18–23; Vienna, Austria.

[26]  Roland M. Enhancing the potential benefits of HIV post-exposure prophylaxis. AIDS 2006; 20 1889–90.
Enhancing the potential benefits of HIV post-exposure prophylaxis.CrossRef | 16954731PubMed |


Full Text PDF (79 KB) Export Citation